Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Stake Reduced by GAMMA Investing LLC

GAMMA Investing LLC reduced its stake in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 25.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,191 shares of the company’s stock after selling 1,104 shares during the quarter. GAMMA Investing LLC’s holdings in Centessa Pharmaceuticals were worth $42,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Cutter Capital Management LP grew its stake in Centessa Pharmaceuticals by 184.3% during the 1st quarter. Cutter Capital Management LP now owns 418,127 shares of the company’s stock worth $6,013,000 after buying an additional 271,051 shares during the last quarter. American Century Companies Inc. boosted its position in Centessa Pharmaceuticals by 1.2% during the 1st quarter. American Century Companies Inc. now owns 1,092,754 shares of the company’s stock worth $15,714,000 after acquiring an additional 13,046 shares during the period. Cerity Partners LLC acquired a new position in Centessa Pharmaceuticals during the 1st quarter worth $471,000. Wellington Management Group LLP boosted its position in Centessa Pharmaceuticals by 20.6% during the 1st quarter. Wellington Management Group LLP now owns 138,767 shares of the company’s stock worth $1,995,000 after acquiring an additional 23,660 shares during the period. Finally, Russell Investments Group Ltd. acquired a new position in Centessa Pharmaceuticals during the 1st quarter worth $3,273,000. 82.01% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Centessa Pharmaceuticals

In related news, insider Mario Alberto Accardi sold 8,322 shares of the stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $15.23, for a total transaction of $126,744.06. Following the completion of the sale, the insider owned 208,163 shares in the company, valued at $3,170,322.49. This represents a 3.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CTO Tia L. Bush sold 35,000 shares of the stock in a transaction that occurred on Wednesday, September 24th. The shares were sold at an average price of $24.00, for a total value of $840,000.00. Following the sale, the chief technology officer owned 121,503 shares of the company’s stock, valued at approximately $2,916,072. The trade was a 22.36% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 205,286 shares of company stock worth $3,993,345 in the last 90 days. Company insiders own 7.09% of the company’s stock.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA stock opened at $23.23 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 10.11 and a quick ratio of 10.12. Centessa Pharmaceuticals PLC Sponsored ADR has a fifty-two week low of $9.60 and a fifty-two week high of $24.57. The stock’s 50-day moving average is $19.12 and its two-hundred day moving average is $15.32. The firm has a market cap of $3.11 billion, a P/E ratio of -12.98 and a beta of 1.57.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03). Analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on CNTA shares. Oppenheimer started coverage on Centessa Pharmaceuticals in a research report on Friday, August 29th. They set an “outperform” rating and a $40.00 price target for the company. Lifesci Capital upgraded Centessa Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, September 3rd. Truist Financial started coverage on Centessa Pharmaceuticals in a research report on Monday, July 21st. They set a “buy” rating and a $30.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Saturday, September 27th. Finally, Chardan Capital reiterated a “buy” rating and set a $30.00 price target on shares of Centessa Pharmaceuticals in a research report on Tuesday, August 12th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Centessa Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $32.38.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.